Back to results
US 9,539,234 B2Granted
Treatment of circadian rhythm disorders
AssigneeVanda Pharmaceuticals Inc.
InventorsMarlene Michelle Dressman, John Joseph Feeney, Louis William Licamele, Mihael H. Polymeropoulos
Life of this patent
Estimating the term…
Abstract
Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
Claims5
A method of treating a patient for a circadian rhythm disorder wherein the patient is being treated with a strong CYP1A2 inhibitor selected from a group consisting of fluvoxamine, ciprofloxacin, and verapamil, the method comprising:
- discontinuing the treatment with the strong CYP1A2 inhibitor;
- and then
- treating the patient with tasimelteion,
- thereby avoiding the use of tasimelteon in combination with the strong CYP1A2 inhibitor.
1 more element
Dependencies are inferred from the claim text.